pantothenic acidWhat was measured
Measured, with no finding
98 endpoints
Show what was measuredHide what was measured
development of dilated cardiomyopathy
no effect
In our patients, long-term treatment has failed to reduce the number of infectious episodes and prevent dilated cardiomyopathy
PMID 14654353 · one of two readings recorded this
number of infectious episodes
no effect
In our patients, long-term treatment has failed to reduce the number of infectious episodes and prevent dilated cardiomyopathy
PMID 14654353 · one of two readings recorded this
baseline nutrient intakes, cognitive decline versus intact cognition
no effect
However, no significant associations between cognitive decline and nutrient intakes were observed among women
PMID 27427336 · one of two readings recorded this
baseline pantothenate intake, cognitive decline versus intact cognition
decreases
Compared with men with intact cognition, the men with cognitive decline had lower baseline intakes of calcium, vitamin A, vitamin B2 , pantothenate, soluble fiber, green vegetables and milk
PMID 27427336 · one of two readings recorded this
cognitive decline (decrease in Mini-Mental State Examination score)
increases
we found that cognitive decline was significantly associated with low intakes of carotene, vitamin B2 , pantothenate, calcium and green vegetables
PMID 27427336 · one of two readings recorded this
C-reactive protein concentration at the third visit
decreases, p = 0.0004, n = 908
P for trend = <0.0001, β = -0.11 (P-value = 0.0004) for PA average (baseline, 2nd, 3rd)
PMID 28739188 · one of two readings recorded this
C-reactive protein concentration at the third visit
decreases, p = 0.001, n = 908
P for trend = 0.001, β = -0.07 (P-value = 0.001) for PA baseline
PMID 28739188 · one of two readings recorded this
change in C-reactive protein concentration from baseline to the third visit
decreases, p = 0.001, n = 908
P for trend = 0.001, β = -0.35 (P-value = 0.001) for PA average (baseline, 2nd, 3rd)
PMID 28739188 · one of two readings recorded this
change in C-reactive protein concentration from baseline to the third visit
decreases, p = 0.002, n = 908
P for trend = 0.002, β = -0.24 (P-value = 0.002) for PA baseline
PMID 28739188 · one of two readings recorded this
brain vitamin B5 concentration
decreases
We found that widespread, severe cerebral deficiency of vitamin B5 occurs in AD
PMID 32416962 · one of two readings recorded this
brain vitamin B5 concentration
decreases
This deficiency was worse in those regions known to undergo severe damage, including the hippocampus, entorhinal cortex, and middle temporal gyrus
PMID 32416962 · one of two readings recorded this
endogenous vitamin B5 concentration in seven post-mortem brain regions, Alzheimer's disease cases vs controls, gas chromatography-mass spectrometry
decreases
Not recorded as a finding: the compound is what was measured, not what was given
We found that widespread, severe cerebral deficiency of vitamin B5 occurs in AD.
PMID 32416962 · one of two readings recorded this
all-cause mortality (hazard ratio, enalapril-folic acid vs enalapril)
no effect, p = 0.47
The enalapril‐folic acid group had 302 all‐cause fatalities (2.9 %) compared to 320 (3.1 %) in the enalapril group (HR = 0.94; 95% CI: 0.81‐1.10; p =.47)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, per SD of plasma vitamin B5)
no effect, p = 0.114, n = 1010
Vitamin B5, ng/mL (Per SD) | 1010 | 505(50.0) | 1.31(0.99,1.74) |.060 | 1.21(0.96,1.52) |.114
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, per SD of plasma vitamin B5)
no effect, p = 0.06, n = 1010
Vitamin B5, ng/mL (Per SD) | 1010 | 505(50.0) | 1.31(0.99,1.74) |.060 | 1.21(0.96,1.52) |.114
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
increases
When Q4‐Q5 were combined, a significant 41% increment (OR = 1.41, 95% CI: 1.03‐1.95) in all‐cause death risk was found compared with Q1‐Q3
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
increases, p = 0.002, n = 404
Q4 ‐ Q5 (≥ 45.7) | 404 | 225(55.70) | 1.53(1.17,2.00) |.002 | 1.41(1.03,1.95) |.034
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
< 66.4 | 327 | 161(49.2) | 178 | 92(51.7) | 0.92(0.61,1.38)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
< 164.7 | 301 | 126(41.9) | 199 | 105(52.8) | 1.48(0.98,2.24)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
increases
< 23.3 | 296 | 136(45.9) | 209 | 125(59.8) | 1.56(1.04,2.34)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
increases
< 90.4 | 253 | 110(43.5) | 244 | 142(58.2) | 1.85(1.24,2.76)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
< 5.3 | 287 | 135(47.0) | 210 | 108(51.4) | 0.99(0.66,1.50)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
Female | 351 | 167(47.6) | 247 | 132(53.4) | 1.24(0.85,1.79)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
< 6.0 | 194 | 101(52.1) | 113 | 59(52.2) | 0.67(0.38,1.18)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
Male | 255 | 113(44.3) | 157 | 93(59.2) | 1.46(0.91,2.35)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
Anqing | 230 | 108(47.0) | 200 | 107(53.5) | 1.16(0.73,1.82)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
Lianyungang | 376 | 172(45.7) | 204 | 118(57.8) | 1.38(0.93,2.05)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
< 13.8 | 323 | 142(44.0) | 175 | 92(52.6) | 1.37(0.90,2.08)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
< 0.2 | 324 | 142(43.8) | 174 | 92(52.9) | 1.33(0.87,2.01)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
< 5.2 | 286 | 144(50.3) | 210 | 115(54.8) | 1.12(0.75,1.69)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
Enalapril‐folic acid | 283 | 130(45.9) | 193 | 108(56.0) | 1.47(0.97,2.22)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)
no effect
Enalapril | 323 | 150(46.4) | 211 | 117(55.5) | 1.20(0.80,1.79)
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 quintiles)
no effect, p = 0.257, n = 202
Q2 (32.9 ‐ < 38.9) | 202 | 95(47.0) | 1.22(0.82,1.79) |.324 | 1.29(0.83,2.01) |.257
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 quintiles)
no effect, p = 0.324, n = 202
Q2 (32.9 ‐ < 38.9) | 202 | 95(47.0) | 1.22(0.82,1.79) |.324 | 1.29(0.83,2.01) |.257
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 quintiles)
no effect, p = 0.395, n = 202
Q3 (38.9 ‐ < 45.7) | 202 | 98(48.5) | 1.33(0.89,1.97) |.162 | 1.22(0.77,1.94) |.395
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 quintiles)
no effect, p = 0.162, n = 202
Q3 (38.9 ‐ < 45.7) | 202 | 98(48.5) | 1.33(0.89,1.97) |.162 | 1.22(0.77,1.94) |.395
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 quintiles)
no effect, p = 0.051, n = 202
Q4 (45.7‐ < 55.0) | 202 | 107(53.0) | 1.63(1.07,2.48) |.023 | 1.62(1.00,2.62) |.051
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 quintiles)
increases, p = 0.023, n = 202
Q4 (45.7‐ < 55.0) | 202 | 107(53.0) | 1.63(1.07,2.48) |.023 | 1.62(1.00,2.62) |.051
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 quintiles)
increases, p = 0.03, n = 202
Q5 (≥ 55.0) | 202 | 118(58.4) | 2.06(1.34,3.15) | <.001 | 1.77(1.06,2.95) |.03
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 quintiles)
increases, p = 0.001, n = 202
Q5 (≥ 55.0) | 202 | 118(58.4) | 2.06(1.34,3.15) | <.001 | 1.77(1.06,2.95) |.03
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 tertiles)
no effect, p = 0.068, n = 336
T2 (37.1‐ < 8.4) | 336 | 171(50.9) | 1.39(1.03,1.87) |.032 | 1.37(0.98,1.92) |.068
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 tertiles)
increases, p = 0.032, n = 336
T2 (37.1‐ < 8.4) | 336 | 171(50.9) | 1.39(1.03,1.87) |.032 | 1.37(0.98,1.92) |.068
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 tertiles)
increases, p = 0.027, n = 337
T3 (≥ 48.4) | 337 | 187(55.5) | 1.80(1.28,2.54) | <.001 | 1.58(1.05,2.38) |.027
PMID 35699663 · one of two readings recorded this
all-cause mortality (odds ratio, vitamin B5 tertiles)
increases, p = 0.001, n = 337
T3 (≥ 48.4) | 337 | 187(55.5) | 1.80(1.28,2.54) | <.001 | 1.58(1.05,2.38) |.027
PMID 35699663 · one of two readings recorded this
all-cause mortality, p for trend across vitamin B5 tertiles
increases, p = 0.024
P for trend | <.001 |.024
PMID 35699663 · one of two readings recorded this
all-cause mortality, trend across vitamin B5 quintiles
increases, p = 0.022
The trend test was significant (p =.022)
PMID 35699663 · one of two readings recorded this
plasma vitamin B5 concentration
increases, p = 0.001
Vitamin B5, ng/mL b | 41.9 (34.8, 52.0) | 40.9 (33.9, 50.3) | 43.7 (36.1, 53.9) |.001
PMID 35699663 · one of two readings recorded this
pantothenic acid concentration
no effect, p = 0.1
CB | 69.1±31.7 (49.9–88.3) | 47.1±21.3 (32.8–61.4) | 0.7 | 0.1 | 3.1 | 2.9 | 1.8 (0.7–4.7) | 1.0 | –0.7
PMID 38820022 · one of two readings recorded this
pantothenic acid concentration
no effect, p = 0.09
CG | 35.3±16.2 (26.3–44.3) | 25.2±8.6 (20.2–30.2) | 0.7 | 0.09 | 4.5 | 2.2 | 1.4 (0.7–3.1) | 1.0 | –0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid concentration
decreases, p = 0.0001
HP | 91.5±28.7 (73.3–109.8) | 49.4±17.8 (39.1–59.7) | 0.5 | <0.0001 | 11.5 | 3.5 | 2.1 (1.02–4.2) | 1.2 | –1.5
PMID 38820022 · one of two readings recorded this
pantothenic acid concentration
no effect, p = 0.2
MED | 27.3±13.7 (19.4–35.2) | 20.4±10.1 (14.5–26.2) | 0.8 | 0.2 | 2.3 | 1.6 | 1.2 (0.5–2.7) | 1.0 | –0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid concentration
decreases, p = 0.02
MTG | 47.1±22.9 (34.5–59.8) | 29.7±18.9 (13.9–24.3) | 0.6 | 0.02 | 6.0 | 3.4 | 2.0 (0.9–4.5) | 1.0 | –0.8
PMID 38820022 · one of two readings recorded this
pantothenic acid concentration
decreases, p = 0.007
MCX | 84.1±42.0 (61.7–106.5) | 45.0±21.5 (32.1–58.0) | 0.5 | 0.007 | 8.1 | 4.9 | 2.7 (1.3–5.8) | 1.8 | –0.9
PMID 38820022 · one of two readings recorded this
pantothenic acid concentration
decreases, p = 0.002
PONS | 32.6±15.4 (19.7–45.4) | 29.3±7.5 (23.0–35.5) | 0.9 | 0.002 | 9.3 | 8.8 | 4.7 (1.7–12.7) | 2.8 | –1.2
PMID 38820022 · one of two readings recorded this
pantothenic acid concentration
decreases, p = 0.008
PVC | 91.5±46.5 (65.7–117.2) | 48.6±20.2 (36.4–60.8) | 0.5 | 0.008 | 7.9 | 3.3 | 1.9 (0.97–3.8) | 1.0 | –0.9
PMID 38820022 · one of two readings recorded this
pantothenic acid concentration
no effect, p = 0.09
PUT | 140.6±89.5 (86.5–194.7) | 81.8±40.9 (58.2–105.3) | 0.6 | 0.09 | 4.5 | 3.1 | 1.9 (0.7–4.7) | 1.0 | –0.7
PMID 38820022 · one of two readings recorded this
pantothenic acid concentration
decreases, p = 0.004
SN | 58.9±25.5 (42.7–75.0) | 29.7±11.8 (21.8–37.6) | 0.5 | 0.004 | 8.0 | 4.9 | 2.7 (1.2–6.2) | 1.7 | –1.2
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
CB | 0.7 | 0.6 | 0.5 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
CG | 0.7 | 0.8 | 0.5 | 0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
ENT | – | – | 0.4 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
HP | 0.5 | 0.9 | 0.5 | 0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
MTG | 0.6 | 0.9 | 0.5 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
MCX | 0.5 | 0.8 | 0.3 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
PVC | 0.5 | 0.9 | 0.4 | 0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
CB | 0.7 | 0.6 | 0.5 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
CG | 0.7 | 0.8 | 0.5 | 0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
ENT | – | – | 0.4 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
GP | – | – | – | 0.4
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
HP | 0.5 | 0.9 | 0.5 | 0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
MFG | – | – | – | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
MTG | 0.6 | 0.9 | 0.5 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
MCX | 0.5 | 0.8 | 0.3 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
PVC | 0.5 | 0.9 | 0.4 | 0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
PUT | 0.6 | – | – | 0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
SN | 0.5 | 0.6 | – | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
CB | 0.7 | 0.6 | 0.5 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
CG | 0.7 | 0.8 | 0.5 | 0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
HP | 0.5 | 0.9 | 0.5 | 0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
MED | 0.7 | 0.6 | – | –
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
MTG | 0.6 | 0.9 | 0.5 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
MCX | 0.5 | 0.8 | 0.3 | 0.6
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
PONS | 0.9 | 0.7 | – | –
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
PVC | 0.5 | 0.9 | 0.4 | 0.5
PMID 38820022 · one of two readings recorded this
pantothenic acid fold-change (cases vs controls)
unclear
SN | 0.5 | 0.6 | – | 0.6
PMID 38820022 · one of two readings recorded this
risk ratio of case values below control 95% CI lower limit
unclear
CB | 69.1±31.7 (49.9–88.3) | 47.1±21.3 (32.8–61.4) | 0.7 | 0.1 | 3.1 | 2.9 | 1.8 (0.7–4.7) | 1.0 | –0.7
PMID 38820022 · one of two readings recorded this
risk ratio of case values below control 95% CI lower limit
unclear
CG | 35.3±16.2 (26.3–44.3) | 25.2±8.6 (20.2–30.2) | 0.7 | 0.09 | 4.5 | 2.2 | 1.4 (0.7–3.1) | 1.0 | –0.6
PMID 38820022 · one of two readings recorded this
risk ratio of case values below control 95% CI lower limit
decreases
HP | 91.5±28.7 (73.3–109.8) | 49.4±17.8 (39.1–59.7) | 0.5 | <0.0001 | 11.5 | 3.5 | 2.1 (1.02–4.2) | 1.2 | –1.5
PMID 38820022 · one of two readings recorded this
risk ratio of case values below control 95% CI lower limit
unclear
MED | 27.3±13.7 (19.4–35.2) | 20.4±10.1 (14.5–26.2) | 0.8 | 0.2 | 2.3 | 1.6 | 1.2 (0.5–2.7) | 1.0 | –0.5
PMID 38820022 · one of two readings recorded this
risk ratio of case values below control 95% CI lower limit
unclear
MTG | 47.1±22.9 (34.5–59.8) | 29.7±18.9 (13.9–24.3) | 0.6 | 0.02 | 6.0 | 3.4 | 2.0 (0.9–4.5) | 1.0 | –0.8
PMID 38820022 · one of two readings recorded this
risk ratio of case values below control 95% CI lower limit
decreases
MCX | 84.1±42.0 (61.7–106.5) | 45.0±21.5 (32.1–58.0) | 0.5 | 0.007 | 8.1 | 4.9 | 2.7 (1.3–5.8) | 1.8 | –0.9
PMID 38820022 · one of two readings recorded this
risk ratio of case values below control 95% CI lower limit
decreases
PONS | 32.6±15.4 (19.7–45.4) | 29.3±7.5 (23.0–35.5) | 0.9 | 0.002 | 9.3 | 8.8 | 4.7 (1.7–12.7) | 2.8 | –1.2
PMID 38820022 · one of two readings recorded this
risk ratio of case values below control 95% CI lower limit
unclear
PVC | 91.5±46.5 (65.7–117.2) | 48.6±20.2 (36.4–60.8) | 0.5 | 0.008 | 7.9 | 3.3 | 1.9 (0.97–3.8) | 1.0 | –0.9
PMID 38820022 · one of two readings recorded this
risk ratio of case values below control 95% CI lower limit
unclear
PUT | 140.6±89.5 (86.5–194.7) | 81.8±40.9 (58.2–105.3) | 0.6 | 0.09 | 4.5 | 3.1 | 1.9 (0.7–4.7) | 1.0 | –0.7
PMID 38820022 · one of two readings recorded this
risk ratio of case values below control 95% CI lower limit
decreases
SN | 58.9±25.5 (42.7–75.0) | 29.7±11.8 (21.8–37.6) | 0.5 | 0.004 | 8.0 | 4.9 | 2.7 (1.2–6.2) | 1.7 | –1.2
PMID 38820022 · one of two readings recorded this
heart rate, respiratory gas exchange, perceived exertion, blood lactate, glucose and free fatty acids during 50-km ride
no effect
There were no significant differences in any of the measured parameters between experimental conditions
PMID 9650731 · one of two readings recorded this
time to complete 2000-m time trial
no effect, p = 0.58
Time to complete the 2000-m time trial was also not significantly different between experimental conditions [PL 178.2 (8.4), AP 170.7 (10.2) s; P=0.58]
PMID 9650731 · one of two readings recorded this
time to complete a 2000-m cycle ergometer time trial after a 50-km steady-state ride
no effect, PL 178.2 (8.4) s vs AP 170.7 (10.2) s, p = 0.58
Not recorded as a finding: the intervention held more than the compound
Time to complete the 2000-m time trial was also not significantly different between experimental conditions [PL 178.2 (8.4), AP 170.7 (10.2) s; P=0.58].
PMID 9650731 · one of two readings recorded this
time to complete a 2000-m cycle time trial after a 50-km steady-state ride
no effect, PL 178.2 (8.4) s vs AP 170.7 (10.2) s, p = 0.58, n = 6
Not recorded as a finding: the intervention held more than the compound
Time to complete the 2000-m time trial was also not significantly different between experimental conditions [PL 178.2 (8.4), AP 170.7 (10.2) s; P=0.58].
PMID 9650731 · one of two readings recorded this